NovoCure: Fourth Quarter Financial Overview

NovoCure Reports Fourth Quarter Financial Results

NovoCure Ltd., headquartered in St. Helier, Jersey, announced on Thursday that it recorded a net loss of $24.5 million for the fourth quarter.

The company’s loss per share came in at 22 cents.

These figures were better than what analysts had anticipated. According to Zacks Investment Research, the consensus among four analysts was a projected loss of 41 cents per share.

During the quarter, the oncology-focused firm generated $174.4 million in revenue, exceeding the $172.9 million forecasted by analysts surveyed by Zacks.

For the entire year, NovoCure reported a total loss of $136.2 million, or $1.22 per share, with annual revenue reaching $655.4 million.

Looking ahead, the company expects its revenue for the coming year to fall between $675 million and $705 million.